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publication, The apparcutiy contradictory findings between our study 
and that of others are potentially rcconcdablc when one appreciates 
that patients with ST.segmcnt depression in the LATE study had at 
,least 2 mm-of ST depression. This group was not specifically addressed 
within the Thrombolysis in Myocardial Infarction 111 study (2) (tem- 
poral window U to IT h vs. 6 to 2J h in the LATE studv). Morcovcr, the 
natural history studies of Lee rt al. (3) have demonstrated that more 
prominent ST segment depression (i.c,.. 22 mm) is highly specific for 
the subsequent diagnosis of acute myocardial infarction and is also an 
indicator of increased risk. It is important to clarity that this group of 
patients did not have unusually prolonged pain but a prolonged time 
from the onset of pain to clinical presentation (i.e.. >6 h). 
We were careful to address obvious limitations of our study in the 
original manuscript and, in particular. did not advocate a change in the 
current thrombolytic therapy algorithm for acute myocardial infarc- 
tion. We remain convinced, however. that some patients with signifi- 
cant ST segment depression may benefit from thrombolytic therapy 
and are pleased that Anderson shares our interest in the need for 
prospective validation. 
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Basal Nitric Oxide Production by Diseased 
Coronary Arteries 
Egashira et al. (I) in their interesting study examined the effects of 
intracoronaty N”-monomethyl-L-arginine (LNMMA. ti inhibitor of 
nitric oxide synthesis) on basal coronary artery tone in Patients with 
variant angina and normal curonary arteries and in control subject 
They reported that tk comtrktor response to LNMMA was signiti- 
that 
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at the non$paslic sites. Their results indicate that the hasal rclrase of 
nitric oxidcis incrcascd rather than decreased at the spastic site in 
patients with variant angina. The authors did not examine the effect of 
atheroma on basal nitric oxide production. hut they acknowledge this 
limitation. This limitation is particularly relevant because many pa- 
tients with spasm have underlying atheroma. 
WC recently examined (2.3) the effects of an intracoronaty infusion 
of LNMMA in patients with chronic stable angina and coronary artcty 
discasc and in patienis with normal coronary arteriograms. The 
diameter of angiographically normal proximal and distal segments and 
coronary sttnoscs was measured by quantitative angiography. In 
response to an LNMMA infusion of 16 pmol’min for 4 min. there was 
a significant reduction (p < 0.01) in lumen diameter of the distal 
segments of diseased arteries and at the site of stenosis but no change 
(p = NS) in lumen diameter of the proximal segments (3). In patients 
with normal coronary artetiograms. there was a significant reduction 
(p < 0.01) in lumen diameter of both proximal and distal segments (2). 
These results indicate that basal nitric oxide production is pre- 
served at the site of stenotic atheromatous plaques. Because it appears 
to be absent in the proximal segments of diseased arteries in which the 
stenoses were mostly located, it is possible that regeneration of basal 
nitric oxide product& has occurred. There is some laboratory evi- 
dence ~osupport this hypothesis because the inducible isoform of nitric 
oxide synrhasc has been found in human atherosclerotic lesions ex 
\ ivo. where it is localized with macrophages. foam cells and vascular 
smooth muscle cells (4). Furthermore. the amount of nitric oxide 
synthase present is related to the severity of the lesion. WC therefore 
propose that atherosclerotic coronary arteries can regenerate basal 
uitric oxide production from an abnormal source. 
DIMITRIS TOUSOULIS. MD, F.4CC 
TOM CRAKE. MD 
GRAHAM DAVIES. MD. FRCP 
Cardiology Cnir 
Hummmmifh Ho.@d 
Du Canr Road 
London U71 Englmd 
Liliini fin,qhm 
COSTAS TENTOLOURIS. MD 
PAVLOS C. IOUTOUZAS. MD. FACC 
Cunfiol~ L’nif 
.Mens Limtmi~ Medicoi Srhool 
I isilisi, sofius 1 I4 
.-lrhcns. (irtw~ 
Ourst~~~totedt~~~hesbthatbasalpodua~ 
release of nitric oxide (NO) is altered at site of spasm in pltients with 
1640 LETTERS TO THE EDITOR JACC Vol. 2X. No. fi 
Nwcmhcr IS. 1Wh:lh37-41 
variant angina and normal coronary angiograms. Our results suggest 
that basal production/relcaseof NO may not be decreased at spastic 
sites in these patients. WC did not investigate the NO-generating 
capacity or vasomotor responses to vasoconstrictor stimuli at the site of 
spasm. Thcrcfore. we cannot conclude that the NO-generating capac- 
ity is augmented at spastic sites. 
Tousoulis ct al. proposed an intriguing hypothesis that atheroscle- 
rotic human corona? arteries can rcgcnerate basal NO production 
from an abnormal source. such as the inducible isoform of NO 
synthase. This hypothesis is based on the fact that patients with variant 
angina have varying degrees of coronary atherosclerosis and that the 
inducibie NO synthase is found in some human coronary arteries 
segments with atherosclerotic lesions. It has heen demonstrated that 
total NO-generating capacity is altered during the process of athero- 
sclerosis (I); however, its precise mechanism has not been well 
understood. There is substantial evidence demonstrating that 
endothelium-dcrivcd NO-rclatcd vasodilation is impaired car!y in 
atherosclerosis (1). However, the results of recent investigations (2-1) 
suggest that endothelial constitutive NO synthase messenger RNA and 
NO protein production are augmented in atherosclerotic vessels. 
These findings suggest that altered NO-related vasomotion during 
athcrosclcrotic process might result from an increased breakdown of 
NO but is not necessarily related to expression of inducible NO 
synthase. It is unknown whether NO that is generated from inducible 
NO synthase contributes to regulation of vasomotor tone. Therefore. I 
believe that the currently available data are not sufficient to support 
tile hypothesis hy Tousoulis et al. Much more investigation remains to 
be done before their hypothesis is substantiated. 
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Cost Efficacy Modeling of Catheter Reuse 
for Percutaneous Transluminal 
Coronary Angioplasty 
I wish to comment on the report by Mak et al. (1) and indirectly on the 
accompanying editorial by Natarajan and Williams (2) Although the 
report by Mak et al. is well wriiten and discusses an impttant topic, it 
seems to me that the authors have made several major assumptions in 
their cost analysis that have gone unstated and unexamined. In 
particular, the authors assume that the price, or cost, of balloon 
catheters is a fixed Quantity and would not change if the results of their 
study were applied widely, even for a subset of patients with stable 
angina. Would the medical device industry really be able to continue to 
charge the same price for balloon catheters if the total number sold 
was reduced by 80% (“best” ease)? How can this posstbly make 
economic sense, since presumably the marginal cost for the production 
and sales of any product is dependent. to some extent. on the volume 
of sales. The authors might ~argue that their analysis is one of 
microeconomics and that the “system” would not be affected if the 
results of their analysis were applied only on a small sca]c..‘to their 
medical center. say. Yet their motivation is clearly macroeconomic’in 
scope hccause they claim that “If coronary angioplasty equipment 
could he reused [based on the results of this and other studies]. the 
total cost could bc potentially reduced hy more than Sl billion per year 
in the Ifnited States.” The systemic implications of this type of inquiry 
arc also implied hy the accompanying editorial. which refers to the 
yearly total charges for angioplasty in the United States of $6 billion. 
The reason that this glaring oversight is important is that this 
report, and others like it. will be used by policymakers interested only 
in short-term cost reduction and not on the larger question of who 
should bear the cost of innovation, including innovation that might 
ultimately (but not necessarily immcdiatcly) reduce overall costs and 
improve care. When policymakers advocate reuse. even in “low risk” 
settings (or any such “cost reduction”). they are reducing the incentive 
for entrepreneurs and inventors to develop new technologies that 
might ultimately improve outcomes. This is not to c~cuse manufactur- 
ers from pricing devices or drugs so as to result in unreasonably high 
protits, but it needs to be remembered that the costs of developing any 
new medical technology arc large and growing. and industry hears the 
majority of such costs. Thnw costs arc in turn huilt into the price of 
each device sold, and if fewer are sold, either the price must rise 
concomitantly or innovation will simply no1 occur. 
Another cost not mentioned is that associated with the medicolegal 
ramifications of reuse. Although reuse of balloon catheters labeled 
.‘single-use only” is not a prima facie violation of standard of care, it 
certainly transfers some of the medicolegal burden to those who 
willingly violate Food and Drug Administration labeling. Thus, one 
can reasonably assume that in some percentage of cases where reused 
catheters cause a complication or additional procedure that might not 
have occurred with d new catheter. a patient will become a plaintiff 
with a willing attomzi and medical expert willing to sa:: tbat reuse 
violates standard of care. Furthermore, in some of those cases the jury 
will agree with the pi&LZ and award damage costs on the order of 10 
to 20 times actual costs. If this series of assumptions is entered into the 
cost-ethcaq model developed by the authors, it might well shift the 
cost-efficacy toward single use. 
A final issue that was not discussed in the report by Mak et al. 
relates to the way in which some part of hospital cost savings are 
implicitly shifted as expenses for physicians. without any clear mech- 
anism for the physicians to recoup those extra expenses. In particular. 
procedures performed with reused catheters are likely to take longer 
(Xl vs. 68 min was used in the study by Mak et al.), with much of that 
extra time requiring exposure of the operator to potentially harmful 
fluoroscopic radiation. Thus, the hospital saves money on catheters 
while physician reimbursement per unit time fails (because he or she is 
not likely to collect more for the same procedure, which takes longer 
simply because of reuse), and his or her long-term risk of radiation 
exposure rises. Perhaps when physicians and hospitals are in a true 
revenue-sharing relationship (such as in a provider-& health 
maintenance organization or foundation such as the Cleveland Clinic). 
this cost shifting is irrelevant, but in most delivery systems and 
hospitals. both for-profit and not-for-profit, including our own Univer- 
sity Medical Center, cost savings by the hospital are not transferred to 
the physicians even if they incur additional expenses. This is, of course, 
an issue that goes well beyond that of balkron catheters and gets into 
the matter of how willing we should be, as physicians and reseatehers. 
